Baseline characteristics of patients vaccinated with a third dose
| Vector | mRNA | |
| n | 27 | 28 |
| Age (years) | 60.9 (15.0) | 58.9 (18.4) |
| Gender: female | 18 (66.7%) | 23 (82.1%) |
| Diagnosis | ||
| Arthritis | 11 (40.7%) | 10 (35.7%) |
| Connective tissue diseases | 7 (25.9%) | 9 (32.1%) |
| Vasculitis | 4 (14.8%) | 4 (14.3%) |
| Multiple sclerosis | 3 (11.1%) | 3 (10.7%) |
| IgG4-related disease | 2 (7.4%) | 2 (7.1%) |
| Months between RTX and screening | 7.0 (6.2) | 6.0 (3.6) |
| Weeks between second vaccination and screening | 8.2 (3.7) | 6.6 (2.3) |
| Patients with detectable B cells | 8 (29.6%) | 10 (35.7%) |
| Concomitant medication | ||
| Any csDMARD | 10 (37.0%) | 16 (57.1%) |
| Methotrexate | 3 (11.1%) | 7 (25.0%) |
| Mycophenolate mofetil | 2 (7.4%) | 4 (14.3%) |
| Azathioprine | 2 (7.4%) | 3 (10.7%) |
| Leflunomide | 3 (11.1%) | 1 (3.6%) |
| Hydroxychloroquine | 0 (0.0%) | 4 (14.3%) |
| Immunoglobulin therapy | 1 (3.7%) | 1 (3.6%) |
| Prednisone | 7 (25.9%) | 8 (28.6%) |
| Prednisone dose (mg) | 5.7 (2.3) | 4.6 (2.7) |
| Primary vaccination with BNT162b2 | 21 (78%) | 21 (75%) |
| Primary vaccination with mRNA-1273 | 6 (22%) | 7 (25%) |
Data are n (%) or mean (SD).
csDMARD defined here as concomitant treatment with at least one of the following: methotrexate, mycophenolate mofetil, azathioprine, leflunomide and hydroxychloroquine.
csDMARD, conventional synthetic disease-modifying antirheumatic drug; IgG4, immunoglobulin G4; RTX, rituximab.